Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 245Carcinoma, Non-Small-Cell Lung 225Prostatic Neoplasms 113Neoplasms 104Multiple Myeloma 90Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 66Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 47Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 43Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Triple Negative Breast Neoplasms 40Recurrence 40Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 33Pancreatic Neoplasms 32Rectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Interventions

trifluridine tipiracil drug combination 1tipiracil 1regorafenib 1Trifluridine 1Tablets 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2 IHC3+ Advanced Colorectal Cancer × 1 year × Clear all
NCT07483684 2026-03-19

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
142 enrolled
Gastrointestinal

HER2 IHC3+ Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡